<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02047604</url>
  </required_header>
  <id_info>
    <org_study_id>C2013-0302</org_study_id>
    <secondary_id>2013-003719-23</secondary_id>
    <nct_id>NCT02047604</nct_id>
  </id_info>
  <brief_title>(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valeant Pharmaceuticals International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valeant Pharmaceuticals International, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of
      Escalating Doses of SAN-300 in Patients with Active Rheumatoid Arthritis with Inadequate
      Response to Disease-Modifying Anti-rheumatic Drug(s).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2013</start_date>
  <completion_date type="Actual">March 23, 2017</completion_date>
  <primary_completion_date type="Actual">February 23, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events</measure>
    <time_frame>10 weeks</time_frame>
    <description>Adverse events data are collected during a 10-week period, which includes 6 weeks of treatment and 4 weeks of follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score (DAS) with 28-joint count using C-reactive protein</measure>
    <time_frame>Change from baseline to the End of Treatment Visit (Week 7)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology 20 (ACR20) responder rate</measure>
    <time_frame>End of Treatment Visit (Week 7)</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in the Health Assessment Questionnaire-Disease index (HAQ-DI)</measure>
    <time_frame>End of Treatment Visit (Week 7)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>MRI findings of the hand and wrist</measure>
    <time_frame>End of Treatment Visit (Week 7)</time_frame>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Cohort A - SAN-300 0.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAN-300 0.5 mg/kg subcutaneous once weekly for six weeks or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B - SAN-300 1.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAN-300 1.0 mg/kg subcutaneous once weekly for six weeks or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C - SAN-300 2.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAN-300 2.0 mg/kg subcutaneous every other week for six weeks or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D - SAN-300 2.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAN-300 2.0 mg/kg subcutaneous once weekly for six weeks or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort E - SAN-300 4.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAN-300 4.0 mg/kg subcutaneous every other week for six weeks or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAN-300</intervention_name>
    <arm_group_label>Cohort A - SAN-300 0.5 mg/kg</arm_group_label>
    <arm_group_label>Cohort B - SAN-300 1.0 mg/kg</arm_group_label>
    <arm_group_label>Cohort C - SAN-300 2.0 mg/kg</arm_group_label>
    <arm_group_label>Cohort D - SAN-300 2.0 mg/kg</arm_group_label>
    <arm_group_label>Cohort E - SAN-300 4.0 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Cohort A - SAN-300 0.5 mg/kg</arm_group_label>
    <arm_group_label>Cohort B - SAN-300 1.0 mg/kg</arm_group_label>
    <arm_group_label>Cohort C - SAN-300 2.0 mg/kg</arm_group_label>
    <arm_group_label>Cohort D - SAN-300 2.0 mg/kg</arm_group_label>
    <arm_group_label>Cohort E - SAN-300 4.0 mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosed with RA for ≥ 6 months according to American College of Rheumatology
             (ACR)/European League Against Rheumatism (EULAR) Classification Criteria 2010

          2. 18 to 75 years of age, inclusive, at the time of informed consent

          3. Swollen joint count of ≥ 6 (66-joint count) and tender joint count of ≥ 6 (68-joint
             count) at Screening and randomization

          4. Inadequate response to therapy or discontinuation of therapy because of unacceptable
             toxicity from at least one prior traditional or biologic disease-modifying
             anti-rheumatic drug (DMARD)

          5. Stable dose of methotrexate (≥ 15 mg/week and ≤ 25 mg/week) for ≥ 6 weeks before
             randomization

        Exclusion Criteria:

          1. Functional Class IV as defined by ACR classification of functional status in RA

          2. History of significant systemic involvement secondary to RA (e.g., vasculitis,
             pulmonary fibrosis, or Felty's syndrome)

          3. History of malignancy or carcinoma in situ within the 5 years before Screening or any
             history of melanoma. Patients with history of excised or adequately treated
             non-melanoma skin cancer are eligible

          4. Evidence of clinically significant uncontrolled concurrent diseases such as
             cardiovascular, endocrinologic, hematologic, hepatic, immunologic, metabolic,
             urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major
             diseases

          5. History of recurrent clinically significant infections

          6. Current active infection or serious local infection (e.g., cellulitis, abscess) or
             systemic infection (e.g., pneumonia, septicemia) within 3 months before randomization

          7. History of severe allergic or anaphylactic reactions to other biologic agents

          8. History of allergies to murine protein

          9. Surgery within 3 months before randomization (other than minor cosmetic surgery or
             minor dental procedures) or plans for a surgical procedure during the Treatment Period
             or Follow-up Period

         10. History of tuberculosis or latent infection currently undergoing treatment

         11. History of malaria

         12. Treatment regimen with prednisone that is either over 10 mg/day (or equivalent dose of
             another corticosteroid) or is not taken at a stable dose of ≤ 10 mg/day for at least 4
             weeks before randomization

         13. Intra-articular corticosteroid injection(s) within 4 weeks before randomization

         14. Any live immunization/vaccination, including against Herpes zoster, within 4 weeks
             before randomization. Live vaccinations must also be avoided throughout the study

         15. Abnormal laboratory value at Screening or Day -1 considered clinically significant

         16. Positive for hepatitis C virus (HCV) antibody or hepatitis B surface antigen (HBsAg)

         17. Positive for human immunodeficiency virus (HIV) antibody

         18. History of tuberculosis or positive QuantiFERON®-TB Gold test (QFT)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 1012</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 1004</name>
      <address>
        <city>El Cajon</city>
        <state>California</state>
        <zip>92020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 1008</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 1011</name>
      <address>
        <city>San Leandro</city>
        <state>California</state>
        <zip>94578</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 1013</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 1003</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 1017</name>
      <address>
        <city>Florissant</city>
        <state>Missouri</state>
        <zip>63031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 1009</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 1019</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 1014</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 1006</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 1001</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2014</study_first_submitted>
  <study_first_submitted_qc>January 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2014</study_first_posted>
  <last_update_submitted>April 26, 2017</last_update_submitted>
  <last_update_submitted_qc>April 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 2a multiple ascending dose, Anti-Very Late Antigen-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antirheumatic Agents</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 5, 2018</submitted>
    <returned>May 7, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

